Axonics (MEX:AXNX) Common Stock : MXN0 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Axonics Common Stock?

Axonics's quarterly common stock declined from Sep. 2023 (MXN0 Mil) to Dec. 2023 (MXN0 Mil) and declined from Dec. 2023 (MXN0 Mil) to Mar. 2024 (MXN0 Mil).

Axonics's annual common stock declined from Dec. 2021 (MXN0 Mil) to Dec. 2022 (MXN0 Mil) and declined from Dec. 2022 (MXN0 Mil) to Dec. 2023 (MXN0 Mil).

Axonics Common Stock Historical Data

The historical data trend for Axonics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Common Stock Chart

Axonics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.06

0.08

0.10

0.09

Axonics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.09	0.09	0.09	0.09	0.08

Axonics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Axonics (MEX:AXNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (MEX:AXNX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

AXNX:USA

Address

26 Technology Drive, Irvine, CA, USA, 92618

Website

https://www.axonics.com

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.